According to the analysis conducted by Cushman & Wakefield Echinox, Romania stands out with a property tax rate of only 0.5% of GDP, compared to the EU average of 1.9%. This low taxation has increased the attractiveness of the local real estate market, providing a favorable framework for owners and investors. In the last decade, the share of property taxes in GDP has decreased, and taxable values have not evolved in tandem with the increase in property prices, affecting revenues from this sector.
Sources
România are cele mai mici taxe pe proprietate din Europa. Media UE este de peste 7 ori mai mare
ANALIZĂ. Un român plăteşte anual până în 100 de euro pentru taxa pe proprietate, de şapte ori mai puţin decât media UE
România are cele mai mici taxe pe proprietate din Europa. Media UE este de peste șapte ori mai mare
România, printre cele mai prietenoase ţări din UE în privinţa taxării proprietăţii / Un român plăteşte anual mai puţin de 100 de euro, de şapte ori mai puţin decât media UE
Cushman & Wakefield Echinox: România, printre cele mai prietenoase ţări din UE în privinţa taxării proprietăţii; un român plăteşte anual mai puţin de 100 de euro, de şapte ori mai puţin decât media UE
Analiză: România se numără printre cele mai prietenoase țări din UE în privința taxării proprietății/ Un român plătește anual sub 100 de euro, de șapte ori mai puțin decât media UE
Latest News
08:06
The U.S. Treasury debt has reached $40.047 trillion, exceeding CBO estimates. The rapid increase in the deficit raises concerns in the financial markets.
07:59
The Washington Post: Russians withdraw billions from banks, fearing that Putin will confiscate their deposits to finance his war
07:46
Hungary: The construction of a riverbed threshold on the Danube has raised the water level by 15-20 cm, preventing the shutdown of the turbines at the Paks nuclear power plant.
07:45
Kiev was the target of a new attack with Russian ballistic missiles. At least six people have died and 12 have been injured.
07:37
An experimental cancer vaccine, developed by Moderna and Merck, has shown promising results in patients with melanoma.
See more news